J Cancer 2013; 4(4):304-314. doi:10.7150/jca.4192
Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC)
1. Division of Medical Oncology, British Columbia Cancer Agency, Vernon, BC, Canada;
2. Department of Biostatistics, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada;
3. Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada.
Humphreys MR, Fernandes KA, Sridhar SS. Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC). J Cancer 2013; 4(4):304-314. doi:10.7150/jca.4192. Available from http://www.jcancer.org/v04p0304.htm
Background: The association between age and outcomes in men with castrate resistant prostate cancer (CRPC) is not well understood.
Objective: We aimed to evaluate CRPC patients to determine if their age at initial diagnosis impacted their cancer specific outcomes.
Design, Setting, and Participants: A retrospective chart review was conducted on 333 consecutive CRPC patients treated at the Princess Margaret Hospital (PMH) between 1995 and 2005. Patients were divided into 4 age categories, (A) <55, (B) 55-64, (C) 65-74 (reference), and (D) ≥ 75 years (yrs).
Outcome Measurements and Statistical Analysis: Primary endpoints included impact of age at diagnosis on overall survival (OS) and on prostate cancer specific survival. Secondary endpoints were time from diagnosis to development of CRPC, time from CRPC to death, and time from diagnosis to bone metastases.
Results and Limitations: The median OS from diagnosis to death was: Group A 5.5 yrs (95% CI 3.0-7.5); Group B 6.7 yrs (95% CI 5.9-8.4); Group C 7.8 yrs (95% CI 6.6-9.3); and Group D 4.3 years (95% CI 2.9-5.0). The hazard ratio (HR) for death in Group D was 2.58 (95% CI 1.58-4.21, p=0.0002); and in Group A was 1.49 (95% CI 0.90-2.46, p=0.13). The duration of hormone sensitivity in Group D was less and predictive of OS, as was Gleason Score ≥8 and Stage 4 disease at diagnosis.
Conclusions: Age at initial diagnosis appears to impact on outcome of patients who subsequently develop CRPC with a bimodal distribution of risk, with the shortest survivals in the ≥75 and <55 groups.
Keywords: Castrate-resistant prostate cancer, overall survival, age at diagnosis, hormone-refractory.
In 2012, an estimated 241,740 men were diagnosed with prostate cancer in the US, of which approximately 28, 170 died from the disease.1 While a diagnosis of prostate cancer in men under the age of 50 is rare, the incidence and mortality increases steadily with age. Several disease-specific factors (e.g. stage, tumor grade, prostate-specific antigen (PSA) level) and patient-specific factors (e.g. co-morbidity, primary treatment modality, and functional status) have been identified as important predictors of survival.2-6 However, the influence of age on outcomes in prostate cancer remains controversial.2,6-9
In a review of 34 studies involving patients with localized prostate cancer, six studies found that young age at diagnosis carried a poor prognosis; five studies showed young age portended a good prognosis, and the remaining 23 studies found no association.9 A more contemporary study analyzing 4003 patients on androgen deprivation therapy (ADT) enrolled in the Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) study from 1995-2007 found men < 65 at diagnosis were at a significantly higher risk of developing metastasis (HR=2.11).10 Supporting this observation was a Surveillance, Epidemiology, and End Results (SEER) database study showing that patients diagnosed at a younger age had worse survival, especially when accompanied by advanced histological grade and stage.11 In contrast, a second SEER based study did not show an impact of age on survival; however, this study also failed to stratify patients into multiple age categories.12
For CRPC patients, Gleason score, PSA, PSA doubling time, hemoglobin (Hgb), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), performance status (PS), pain at baseline, chemotherapy type, ethnicity, presence of visceral disease and advanced age have all been identified as factors that impact OS.13-15 Only one study, by Halabi et al, has directly assessed the impact of age on outcome in CRPC.14 This study, which utilized pooled data from 8 CALGB trials, found that men aged 80-89 were at increased risk for death, compared to their younger counterparts. Interestingly, they also reported that younger men (age 50-59) were at a 25% increased risk of clinical progression and 26% increased risk of prostate cancer death compared to those aged 70-79 but this did not translate into a decreased OS (p=0.172).14
Understanding the relationship between age and outcomes may not only have prognostic implications, but in the era of molecular targeted therapy and personalized medicine may also have important therapeutic implications. In our study, we evaluated 333 consecutive CRPC patients to determine if age at initial diagnosis of prostate cancer impacted on OS.
Patients and Methods
Following ethics approval, a retrospective chart review was performed on 3295 consecutive prostate cancer patients referred to the PMH between January 1, 1995 and December 31, 2005. PMH registry database and chart review identified 333 patients that fulfilled inclusion criteria. Vital statistics were obtained by linking to the Cancer Care Ontario database (accessed July 31, 2012).
Eligible patients had histologically confirmed adenocarcinoma of the prostate with disease progression after androgen ablation as indicated by two consecutive PSA rises or with measurable disease progression as defined by RECIST criteria.16 Summary statistics for demographic and clinical factors were generated for each case at diagnosis and during treatments. The Charlson Comorbidity Index (CCI) was used as an assessment of comorbidities at the time of diagnosis.17,18
The primary endpoints were the impact of age at diagnosis on OS and on prostate cancer specific survival. Secondary endpoints included impact of age on a) time from diagnosis to development of CRPC b) time from CRPC to death and c) time from diagnosis to bone metastases. A prespecified subset analysis evaluated the impact of age on OS, progression free survival (PFS) and PSA-PFS in patients receiving chemotherapy. PFS was defined as a composite of PSA progression, bone progression, nodal or visceral progression, and death, while PSA-PFS was defined by PCWG2 criteria.19
OS curves were created by the Kaplan-Meier approach. Univariate and multivariate Cox PH regression analyses were conducted. All covariates were entered into the multivariate model. All statistical analyses were performed using SAS version 9.1 and R version 2.7.1. All statistical tests were two-sided and p-values ≤ 0.05 were considered statistically significant. Multiple imputation methodology was performed when indicated for incomplete data sets. Patients lost to follow-up were censored at last known contact. In order to account for an uneven distribution of patients across the 4 age groups we performed our sample size calculation post-hoc based on the smallest group. The total sample size required to detect the increased risk of death of 32% on multivariate analysis (HR=1.32) identified in this study, at a power of 80% with a 2-sided p=0.05 was 293 patients.
Amongst the 333 eligible CRPC patients, average age at diagnosis was 65; most patients had Gleason scores of 8-10; median PSA was 146, LDH 223, ALP 144 and Hgb 120. A greater proportion of patients in Groups A and D presented with Stage 4 disease. Group D patients had more comorbidities and were less likely to have undergone definitive local therapy. However, they achieved a quicker PSA nadir on ADT at an average of only 9.2 months (mos). Prior to initiation of chemotherapy, Group D patients had poorer PS and were less likely to receive chemotherapy than younger patients (Table 1).
Baseline characteristics of study population (n=333).
|Age at Diagnosis (years)||Group A < 55||Group B 55 - 64||Group C 65 - 74||Group D ≥ 75||Total|
|n (%)||30 (9%)||124 (37%)||145 (43%)||35 (10%)||333(100%)|
|Characteristics at Time of Diagnosis|
|Stage at Dx†|
|1-2||4 (14%)||19 (17%)||40 (31%)||7 (21%)||70 (23%)|
|3||5 (17%)||38 (34%)||35 (27%)||8 (24%)||86 (29%)|
|4||20 (69%)||54 (49%)||53 (41%)||18 (55%)||145 (48%)|
|PSA at Dx|
|0 - <10||10 (40%)||23 (23%)||31 (28%)||6 (18%)||70 (26%)|
|10 - <20||2 (8%)||22 (22%)||24 (21%)||2 (6%)||50 (18%)|
|20 - <100||7 (28%)||34 (34%)||33 (34%)||11 (33%)||90 (33%)|
|≥100||6 (24%)||22 (22%)||19 (17%)||14 (42%)||61 (23%)|
|Prostatectomy at Dx†|
|No||24 (80%)||94 (77%)||120 (83%)||34 (97%)||272 (82%)|
|Yes||6 (20%)||28 (23%)||24 (17%)||1 (3%)||59 (18%)|
|RT at Dx|
|No||19 (63%)||80 (66%)||89 (62%)||28 (80%)||216 (65%)|
|Yes||11 (37%)||42 (35%)||55 (38%)||7 (20%)||115 (35%)|
|Gleason at Dx|
|<=6||2 (7%)||6 (6%)||14 (11%)||3 (11%)||25 (9%)|
|7||8 (30%)||34 (33%)||40 (33%)||5 (18%)||87 (31%)|
|8-10||17 (63%)||63 (61%)||68 (56%)||20 (71%)||168 (60%)|
|CCI at time of Dx†|
|0||22 (73%)||59 (50%)||56 (40%)||8 (25%)||145 (45%)|
|1-2||7 (23%)||46 (39%)||66 (47%)||16 (50%)||135 (42%)|
|3-4||1 (3%)||9 (8%)||14 (10%)||8 (25%)||32 (10%)|
|>4||0 (0%)||4 (3%)||3 (2%)||0 (0%)||7 (2%)|
|Time in Years to Bone Mets or Death from Dx|
|Characteristics at Time of CRPC|
|PSA Nadir on ADT†|
|<4||19 (63%)||85 (79%)||92 (75%)||18 (56%)||214 (73%)|
|≥4||11 (37%)||23 (21%)||31 (25%)||14 (44%)||79 (27%)|
|Time in Months to PSA Nadir from ADT Initiation (mean) †||22.5||19.6||21.5||9.21||20.0|
|No||21 (70%)||101 (82%)||125 (86%)||30 (86%)||277 (83%)|
|Yes||9 (30%)||22 (18%)||20 (14%)||5 (14%)||56 (17%)|
|Antiandrogen Withdrawal Response|
|No||19 (63%)||85 (79%)||92 (75%)||18 (56%)||195 (74%)|
|Yes||11 (37%)||23 (21%)||31 (25%)||14 (44%)||68 (26%)|
|Characeristics at Time of Chemotherapy Consideration|
|ECOG Performance Status†|
|0-1||27 (96%)||83 (72%)||91 (69%)||16 (53%)||217 (71%)|
|2||1 (4%)||26 (22%)||29 (22%)||3 (10%)||59 (19%)|
|3-4||0 (0%)||7 (6%)||12 (9%)||11 (37%)||30 (10%)|
|PSA Doubling Time†|
|0-30||9 (32%)||30 (26%)||28 (21%)||3 (9%)||70 (23%)|
|≥30-60||6 (21%)||46 (40%)||38 (29%)||13 (38%)||103 (33%)|
|≥60||13 (46%)||39 (34%)||67 (50%)||18 (53%)||137 (44%)|
|Median PSA (mg/dL)||113||158||131||154||146|
|Median LDH (IU/L)||236||244||223||208||223|
|Median ALP (IU/L)||161||149||144||123||144|
|Median Hgb (g/L)||124||120||120||115||120|
|Docetaxel||11 (37%)||30 (26%)||29 (20%)||5 (15%)||75 (23%)|
|Mitoxantrone||6 (20%)||27 (23%)||47 (33%)||12 (35%)||92 (29%)|
|Docetaxel and Mitoxantrone||8 (27%)||37 (32%)||29 (20%)||0 (0%)||74 (23%)|
|None||5 (17%)||20 (17%)||37 (26%)||17 (50%)||79 (25%)|
|Other||0 (0%)||2 (2%)||0 (0%)||0 (0%)||2 (<1%)|
Abbreviations: PSA, prostate specific antigen; Dx, diagnosis; RT, radiotherapy; CCI, Charleston comorbidity index, CRPC, castration resistant prostate cancer; ADT, androgen deprivation therapy; ECOG, Eastern Cooperative Oncology Group; LDH, lactose dehydrogenase; ALP, alkaline phosphatase; Hgb, hemoglobin (†, meets p<0.05 statistical significance per Fisher's Exact Test or Chi-squared test).
Time from Initial Diagnosis to Death
After a median follow-up of 6.6 yrs, 255 of 333 patients (77%) had died. Median survival in Group A was 5.5 yrs; Group B was 6.7 yrs; Group C was 7.8 yrs; and Group D was 4.3 yrs with the differences between the groups being statistically significant (log-rank p<0.0001, Table 2a, Fig 1). For the entire cohort, overall 5-yr survival rate from diagnosis was 62%, but 10-yr survival rate was only 28%. As shown in Table 2b, on univariate analysis there was a statistically significant increased risk of death associated with age ≥75, HR of 2.58 (p=0.0002). Patients <55 also showed a trend towards an increased risk of death with a HR of 1.49 (p=0.13). On multivariate analysis, age ≥75 was associated with the largest HR for death (2.84, p<0.0001), followed by stage 4 disease (HR=2.83, p<0.0001), and Gleason ≥8 (HR=2.57, p=0.008; Table 2b).To account for non-prostate cancer deaths, which could be a source of bias, the above analyses were repeated for disease specific survival. The results remained similar to the OS analysis with HR of 1.7 (p=0.04) for Group D and 1.5 (p=0.09) for Group A on univariate analysis. On multivariate analysis the HR was preserved in the older cohort but the statistical significance was lost (HR=1.6; p=0.16). Multivariate analysis suggested that stage at diagnosis was the primary driver (HR=2.2, p=0.004) for increased risk of death. As noted above, patients at both extremes of age had an increased proportion of advanced stage disease at diagnosis.
When time from diagnosis to the development of bone metastasis and duration of hormone sensitivity were included in the analysis of OS, both were independently predictive of OS from diagnosis (HR=0.71 per 1 yr increase, p<0.001, and HR=0.80 per 1 yr increase, p<0.001, respectively). The time from diagnosis to death was not significantly influenced by CCI. Non-docetaxel based chemotherapy was associated with a worse prognosis compared to no therapy (HR=2.01, p=0.002). Time from initial diagnosis to death was divided into two clinically relevant time frames: a) time from initial diagnosis to CRPC and b) time from CRPC to death, and analyzed independently.
a)Time from Diagnosis to CRPC
Time from initial diagnosis to CRPC was 2.1 yrs (Group A), 2.8 yrs (Group B), 3.4 yrs (Group C), and 1.3 yrs (Group D) (log-rank p<0.0001, Table 3, Fig 2). Multivariate analysis again yielded the largest HR for age ≥75 (HR 2.64, p=0.0001), followed by Gleason score ≥8 (HR 2.55, p=0.004), and stage 4 disease at presentation (HR=2.21, p<0.0001).
b)Time from CRPC to death
At the time of data-lock, 77% (230/300) deaths were observed. The median time from CRPC to death was 2.9 yrs. There was no statistically significant difference in OS between the age stratified cohorts (Fig 3). The key factors that were independently predictive of adverse survival from CRPC to death were presence of visceral metastasis, absolute PSA nadir on ADT (>4 vs ≤4ng/ml), time to PSA nadir on ADT (<6 vs ≥ 6 mos), and duration of hormone sensitivity determined by time from starting a gonadotropin releasing hormone (GnRH) agonist to CRPC (<12 vs ≥12 mos, Table 4). Anti-androgen withdrawal response occurred in 26% of patients and did not impact OS. There was no discernible difference between patients receiving docetaxel compared to no chemotherapy, but CRPC patients receiving non-docetaxel chemotherapy exhibited a reduced survival (HR=2.00, p<0.0001). Variables measured at diagnosis did not influence survival from CRPC. We also found that age <55 at the time of CRPC diagnosis was associated with a trend to increased risk of death on univariate analysis (HR=1.78, p=0.13) but not on multivariate analysis (HR=1.19, p=0.62, Fig 4).
Overall Survival (From Initial Diagnosis to Death).
|Age (y)||Group A < 55||Group B 55 - 64||Group C 65 - 74||Group D ≥ 75|
|Med. Survival (years) (95% CI†)||5.5 (3.0-7.5)||6.7 (5.9-8.4)||7.8 (6.6-9.3)||4.3 (2.9-5.0)|
|5y Survival (%) (95% CI)||52 (33-68)||67 (58-75)||66 (58-73)||35 (19-51)|
|10y Survival (%) (95% CI)||27 (13-44)||27 (19-36)||33 (25-42)||10 (2-25)|
Abbreviations: y, years;Med, median; CRPC, castration resistant prostate cancer; († depicts log rank test statistical significance p<0.0001).
Univariable and Multivariable Cox-PH Regression Analysis of Overall Survival.
|HR (95% CI)||p-value||HR (95% CI)||p-value|
|Group A <55||1.49 (0.90-2.46)||0.13||1.32 (0.77-2.27)||0.32|
|Group B 55 - 64||1.05 (0.73-1.50)||0.81||0.98 (0.68-1.42)||0.91|
|Group C 65 - 74||Reference||Reference|
|Group D ≥75||2.58 (1.58-4.21)||0.0002||2.84 (1.70-4.74)||<.0001|
|Stage at Dx||<.0001||<.0001|
|3||0.94 (0.61 - 1.46)||0.79||0.92 (0.58 -1.47)||0.72|
|4||3.04 (2.03 - 4.55)||<.0001||2.83 (1.70 -4.72)||<.0001|
|7||1.31 (0.65 - 2.61)||0.45||1.41 (0.68 -2.93)||0.36|
|8-10||2.34 (1.22 - 4.50)||0.01||2.57 (1.28 -5.17)||0.008|
|CCI at Dx||0.71||0.52|
|1-2||0.95 (0.68 - 1.32)||0.75||0.91 (0.64 -1.31)||0.62|
|3+||1.17 (0.72 - 1.91)||0.53||1.23 (0.72 -2.08)||0.45|
|RT at Dx||0.001||0.32|
|Yes||0.58 (0.42 - 0.80)||0.82 (0.56 -1.21)|
|PSA at Diagnosis||0.003||0.34|
|0 - <10||Reference||Reference|
|10 - <20||0.87 (0.55 - 1.37)||0.55||0.95 (0.58 -1.54)||0.82|
|20 - <100||0.83 (0.56 - 1.24)||0.37||0.71 (0.46 -1.08)||0.10|
|≥100||1.84 (1.17 - 2.89)||0.008||0.75 (0.45 -1.26)||0.28|
|Prostatectomy at Dx||0.08||0.06|
|Yes||0.69 (0.46 - 1.05)||0.65 (0.41 -1.02)|
Median Time from Diagnosis to Development of CRPC.
|Age (y)||Group A < 55||Group B 55 - 64||Group C 65 - 74||Group D ≥ 75|
|Med. Time (y) from Dx to CRPC (95% CI)†||2.1 (1.5-2.9)||2.8(1.8-3.7)||3.4(2.7-4.5)||1.3(0.9-1.9)|
|5-Year CRPC-free Survival (%) (95% CI)||17 (6-32)||32 (23-40)||40 (32-48)||3(0.2-13)|
Abbreviations: Dx, diagnosis;y, years; CRPC, castration resistant prostate cancer; m, months, († depicts log rank test statistical significance p<0.0001).
Univariable and Multivariable Cox-PH Regression Analysis of the Time from CRPC to Death.
|HR (95% CI)||p-value||HR (95% CI)||p-value|
|Age at Diagnosis (years)||0.19||0.19|
|Group A <55||0.96 (0.61 - 1.52)||0.85||0.73 (0.44 - 1.20)||0.21|
|Group B 55 -64||0.82 (0.61 - 1.11)||0.19||0.76 (0.55 - 1.05)||0.10|
|Group C 65 - 74||Reference||Reference|
|Group D≥75||1.30 (0.86 - 1.98)||0.21||1.07 (0.68 - 1.69)||0.76|
|Presence of Visceral Disease (Yes vs No)||1.95 (1.41-2.70)||<0.0001||2.01 (1.40 - 2.88)||<0.0001|
|Absolute PSA Nadir on ADT (≥4 vs <4 ng/ml)||1.99 (1.47 - 2.69)||<0.0001||1.90 (1.37 - 2.64)||<0.0001|
|Time to Nadir on ADT (<6 vs ≥6 months)||2.27 (1.71 - 3.01)||<.0001||1.64 (1.19 - 2.26)||0.003|
|Duration of Hormone Sensitivity (≥12 vs <12 mo)||0.61 (0.42 - 0.88)||0.009||0.66 (0.46 - 0.94)||0.02|
|PSA at Diagnosis||0.05||0.01|
|0 - <10||Reference||Reference|
|10 - <20||0.85 (0.55 - 1.32)||0.46||0.81 (0.49 - 1.33)||0.40|
|20 - <100||0.67 (0.45 - 0.99)||0.67||0.64 (0.43 - 0.94)||0.02|
|≥100||1.12 (0.75 - 1.69)||0.58||0.48 (0.29 - 0.79)||0.004|
|Gleason at Diagnosis||0.09||0.63|
|7||0.92 (0.54 - 1.57)||0.76||0.88 (0.51 - 1.52)||0.65|
|8-10||1.30 (0.79 - 2.15)||0.30||1.02 (0.59 - 1.73)||0.96|
|CCI at time of diagnosis||0.50||0.22|
|1-2||0.93 (0.70 - 1.24)||0.64||0.80 (0.59 - 1.10)||0.17|
|3+||1.20 (0.79 - 1.82)||0.39||0.81 (0.51 - 1.26)||0.35|
|Stage at Diagnosis||<0.0001||0.06|
|3||0.75 (0.51 - 1.11)||0.15||1.01 (0.68 - 1.50)||0.20|
|4||1.53 (1.09 - 2.17)||0.02||2.21 (1.42 - 3.44)||0.59|
|Time from Dx to CRPC (per 1 month increase)||0.994(0.991-0.998)||0.002||0.996 (0.992 - 1.001)||0.11|
|Peripheral Anti-androgen Withdrawal Response|
|Yes||0.89 (0.65 - 1.23)||0.47||0.85 (0.58 - 1.23)||0.39|
Percent survival over time, stratified by age at initial diagnosis (n=333).(Click on the image to enlarge.)
Percent not progressing from diagnosis to CRPC over time, stratified by age at initial diagnosis. (n=314).(Click on the image to enlarge.)
Percent not progressing from CRPC to death over time, stratified by age at initial diagnosis (%).(Click on the image to enlarge.)
Percent not progressing from CRPC to death over time, stratified by age at CRPC diagnosis (%).(Click on the image to enlarge.)
Bone metastasis-free survival from diagnosis over time, stratified by age at initial diagnosis (n=333).(Click on the image to enlarge.)
Time from Initial Diagnosis to Bone Metastasis
Patients in Group A, showed a median time from initial diagnosis to bone metastasis of only 1.2 yrs (95% CI 0.03-2.75) compared to 4.1 yrs (2.89-5.50) for Group C (Table 1). Figure 5 demonstrates that patients in Groups A and D both had an increased risk of developing bone metastases, and the curves continue to diverge for approximately ten years. Group A patients on univariate analysis had a HR of 1.55, bordering on statistically significance (p=0.067) and on multivariate analysis had a HR of 1.49 (p=0.13).
OS Multivariate Cox PH Regression of Significant Covariates in CRPC Patients Receiving Chemotherapy from Start of Chemotherapy.
|Age at Diagnosis (years)||0.58|
|Group A <55||65 to 74||1.18||0.70-2.01||0.96|
|Group B 55 to 64||65 to 74||0.88||0.61-1.28||0.50|
|Group D ≥ 75||65 to 74||0.71||0.30-1.64||0.42|
|PSA Doubling Time||0.003|
|≥ 0 and < 30 days||<0 or ≥ 60||1.86||1.21-2.86||0.005|
|≥ 30 and <60 days||<0 or ≥ 60||0.96||0.65-1.40||0.64|
|Type of Chemotherapy|
Abbreviations: OS, overall survival; CRPC, castration resistant prostate cancer; PSA, prostate specific antigen; ECOG, Eastern Cooperative Oncology Group; ALP, alkaline phosphatase; Hgb, hemoglobin.
Chemotherapy Overall Survival Subset Analysis
A subset analysis of 246 chemotherapy treated patients, with average follow-up of 1.1 yrs, observed 193 deaths. The median survival was 55 weeks (wks) with no differences on the basis of age stratification. Median PFS was 24.4 wks and median PSA-PFS was 26 wks, respectively, with no statistical difference between age groups. On multivariate analysis of significant covariates, PSA doubling time of less than 1 month, ECOG PS ≥3, and baseline Hgb less than 100 g/L were consistent predictors of shorter OS, PFS, and PSA-PFS. Elevated LDH was an important predictor of OS but not PFS or PSA-PFS. Treatment with docetaxel chemotherapy was statistically protective versus non-docetaxel based regimens for both OS and PFS on multivariate analysis (HR=0.47, p=0.0001, and HR=0.64, p=0.02, respectively, Table 5).
In this study of 333 CRPC patients, treated over a 10 yr period, advanced age (≥75) at the time of initial prostate cancer diagnosis is associated with a statistically significant shorter OS, from the time of initial diagnosis to death. Interestingly, we also show a trend towards worse survival in patients who were ≤55 at the time of initial diagnosis. This is similar to the SEER study showing a bimodal distribution of risk, based on age at diagnosis especially in patients with advanced stage or histology.14
Patients ≥75 had a decreased OS (and prostate cancer specific OS) likely due to a shorter duration from diagnosis to CRPC. Our data suggests this is related to both advanced stage at diagnosis and a statistically significant shorter duration of hormone sensitivity. This latter finding is consistent with results presented by Hussain et al where a shorter duration of response to hormonal therapy correlated with a decreased OS.20 One reason for the reduced duration of hormone sensitivity may be lower pretreatment testosterone levels in the elderly population; though not directly measured in our study this has been linked to worse survival. 21
Patients who were <55 at the time of diagnosis showed an unexpected trend towards worse survival (5.5 yrs versus 7.8 yrs) despite having fewer comorbidities and a better performance status. This group developed bone metastases earlier, a result that bordered on being statistically significant. At presentation a greater proportion of these patients had low PSA levels (<10ng/ml), stage 4 disease, and visceral metastases. Further studies are needed to understand if there are unique host or tumor factors that lead to this presentation in younger patients or if these tumors are more poorly differentiated and non-PSA producing. A positive family history was also found in the majority of these patients, raising the question of whether there is a link between early onset prostate cancer, family history and genetics. Indeed such a link has been described. In one study up to 43% of patients under 55 had a genetic predisposition.22,23 While several mechanisms have been described, recent attention has focused on genes, such as the BRCA gene, which when mutated has been shown to confer an increased risk of recurrence following local therapy and increased prostate cancer-specific death (HR 5.16).24-26 Understanding mutations like BRCA may have important screening, diagnostic and therapeutic implications.
In terms of survival from CRPC to death, neither age at diagnosis, nor age at onset of CRPC impacted survival. This is consistent with an analysis of the TAX 327 study where age was not a statistically significant prognostic factor.27 Our results perhaps differ slightly from those presented by Halabi et al, which showed CRPC patients over 80 had worse outcomes than other age groups, but the age categories in these two studies were overlapping (≥75 and ≥ 80), there were relatively few patients in the advanced age groups in both studies, and the Halabi study predated the use of docetaxel chemotherapy.14 The key factors that were independently predictive of survival from CRPC to death were absolute PSA nadir on ADT (<4 vs ≥4ng/ml), time to PSA nadir on ADT (<6 mo vs ≥ 6mos), duration of hormone sensitivity (<12 vs ≥12 mos), presence of bone metastases, and presence of visceral metastases (Table 4).
In patients receiving chemotherapy, consistent with other studies, a significantly reduced risk of death was seen for those who received docetaxel-based therapy.28,29 We did not find that the mortality associated with chemotherapy was age-related, suggesting patients were appropriately selected and confirmed earlier observations that there is no strict age criteria that should preclude appropriate treatment.17 This is an important finding since even in our study we show that patients who were ≥75, were less likely to receive chemotherapy than younger patients. Given both the palliative and survival benefits of chemotherapy, its use should therefore not be dictated by age alone.
In this study we evaluated CRPC patients over a 10 yr period and showed that age at initial diagnosis of prostate cancer did influence outcomes with a bimodal survival curve. Poorer outcomes were most evident in the elderly (>75) age group with an overall survival of only 4.3 yrs. In this group, the duration of hormone sensitivity was shorter, possibly owing to the reduced testosterone levels at baseline. Based on these results, it may be reasonable to prepare the very elderly patients that hormonal therapy may only have short term benefits and that chemotherapy may be needed to optimize disease control. A similar approach may also be warranted in younger patients where again outcomes appeared worse. One strategy to improve outcomes overall may be with the use of novel more effective hormonal treatments, such as abiraterone acetate (a CYP17 inhibitor) or enzalutamide (a new generation androgen receptor antagonist) earlier in the course of the disease to delay the development of CRPC; or alternatively introducing chemotherapy earlier in the course of treatment, especially in the younger and fitter patients. These are approaches currently under evaluation in clinical trials. Although age at initial diagnosis requires validation, it could be an important stratification factor for patients on clinical trials. As we look to the future, a more comprehensive understanding of prostate cancer from both a prognostic and molecular perspective may open further diagnostic and therapeutic avenues, allowing tailoring of therapy and ultimately lead to better outcomes in the future.
The authors would like to thank Cancer Care Ontario (CCO) for linking study patients with the CCO vital statistics registry, and Princess Margaret Hospital / University Health Network for providing biostatistics support and funding this study. The authors would also like to specifically thank Alisha Albert-Green, Manjula Maganti, and Melania Pintilie for their statistical support and expertise.
The authors have declared that no competing interest exists.
1. Siegel R, Naishadham D, Jemel A. et al. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29
2. Kattan M, Cuzick J, Fisher G. et al. A nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer. 2007;110:69-74
3. Shipley WU, Thames HD, Sandler HM. et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281(17):1598-1604
4. Klotz K. Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy. Nat Clin Pract Urol. 2008;5(7):362-363
5. Tewari A, Gamito E, Crawford J. et al. Biochemical recurrence and survival prediction models for the management of clinically localized prostate cancer. Clin Prostate Canc. 2004;2(4):220-227
6. Zagars G, von Eschenbach A, Ayala A. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer. 1993;72:1709-1725
7. Sandhu D, Munson K, Benghiat A. et al. Natural history and prognosis of prostate carcdinoma in adolescents and men under 35 years of age. Br J Urol. 1992;69:525-529
8. Aprikian A, Zhang Z, Fair W. Prostate adenocarcinoma in men younger than 50 years. Cancer. 1992;74(6):1768-1777
9. Parker C, Gospodarowicz M, Warde P. Does age influence the behavior of localized prostate cancer?. BJU Int. 2001;87:629-637
10. Abouassaly R, Paciorek A, Ryan C. et al. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy. Cancer. 2009;115:4470-4476
11. Merrill RM, Bird JS. Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control. 2002;13:435-443
12. Tward JD, Lee CM, Pappas LM. et al. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer. 2006;107:2392-2400
13. Halabi S, Small E, Kantoff P. et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-1237
14. Halabi S, Vogelzang N, Ou S. et al. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 cancer and leukemia group B (CALGB) studies. J of Urol. 2006;176:81-86
15. Armstrong AJ, Garett-Mayer ES, Yang YO. et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res. 2007;13(21):6396-6403
16. Therasse P, Arbuck S, Eisenhauer E. et al. New guidelines to evaluated the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216
17. Hall W, Jani A, Ryu J. et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer and Prostatic Diseases. 2005;8:22-30
18. Charlson M, Pompei P, Ales K. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383
19. Scher HI, Halabi S, Tannock I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148-1159
20. Hussain MH, Goldman B, Tangen CM. et al. Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916. J Clin Oncol. 2009;27(15):2450-2456
21. Chodak G, Vogelzang N, Caplan R. et al. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex study group. JAMA. 1991;265(5):618-621
22. Steinberg G, Carter B, Beaty T. et al. Family history and the risk of prostate cancer. Prostate. 1990;17:337-347
23. Carter B, Beaty T, Steinberg G. et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci. 1992;89:3367-3371
24. Forrest M, Edwards S, Houlston R. et al. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer and Prostatic Diseases. 2005;8:95-102
25. Xu J, Zheng SL, Isaacs SD. et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. PNAS. 2010;107(5):2136-2140
26. Gallagher DJ, Gaudet MM Pal P. et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16(7):2115-2121
27. Armstrong AJ, Garret-Mayer ES, Yang YO. et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13:6396-6403
28. Tannock IF, DeWit R, Berry W. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512
29. Petrylak D, Tangen C, Hussain M. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520
Corresponding author: Srikala S. Sridhar MD MSc FRCPC, Medical Oncologist, Princess Margaret Hospital, Assistant Professor, University of Toronto. 5-222, 610 University Avenue, Toronto, ON, Canada M5G 2M9, TEL: 416-946-4501 2662 FAX: 416-946-6546. Srikala.Sridharca.